The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for certain patients with muscle-invasive bladder cancer (MIBC) after bladder removal surgery (cystectomy). The FDA also approved Signatera CDx as the companion diagnostic test used to identify eligible patients. This approval marks an important step toward more personalized […]

A bladder cancer diagnosis is hard enough. Learning it has crossed into muscle tissue — that it’s now muscle-invasive bladder cancer (MIBC) — hits differently. The urgency escalates. The treatment conversation changes completely. But here’s what matters most right now: understanding your full range of muscle-invasive bladder cancer treatment options puts you back in control. […]

There’s encouraging news for people diagnosed with muscle-invasive bladder cancer (MIBC). New research presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium showed that a combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) may help patients live longer and reduce the risk of the cancer returning, which is outperforming the current standard […]

Radical cystectomy, the surgical removal of the bladder, is one of the standard treatments for muscle-invasive bladder cancer. Life after bladder removal is undeniably different. Your body works in a new way and routines shift. The emotional weight of that change is real and valid. With some adjustment, life after bladder removal can still be […]